REVB - Revelation Biosciences, Inc. News

Discover

REVB

Revelation Biosciences, Inc.

1.12

1 x 1.10

1 x 1.18

bid

ask

0.03

2.61%

10:58 AM

timesize

Ytd	-65.00%
1y	-90.82%

1.12

day range

1.16

0.88

52 week range

12.72

Open	1.15	Prev Close	1.15	Low	1.12	High	1.16	Mkt Cap	4.49M
Vol	7.40K	Avg Vol	53.08K	EPS	-18.45	P/E	-0.06	Forward P/E	-0.13
Beta	-0.12	Short Ratio	0.11	Inst. Own	8.90%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-07	50-d Avg	1.04	200-d Avg	2.37	1yr Est	12.75

REVB News

accessnewswire.com

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "C

benzinga.com

Revelation Biosciences' Board Implements Shareholder Rights Plan, Declares Dividend Distribution Of

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinic

accessnewswire.com

Revelation Biosciences Announces Adoption of Stockholder Rights Plan

SAN DIEGO, CA / ACCESS Newswire / July 10, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "C

accessnewswire.com

Revelation Biosciences Expands Acute Kidney Injury Advisory Board

SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Co

accessnewswire.com

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

SAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Co

accessnewswire.com

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Com

benzinga.com

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

accessnewswire.com

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "C

accessnewswire.com

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

- A majority of CKD patients present with cellular inflammation and immunoparalysis predose - -Gemin

accessnewswire.com

REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "

accessnewswire.com

Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "

defenseworld.net

Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update

Revelation Biosciences, Inc. (NASDAQ: REVB - Get Free Report) was the target of a large drop in shor

accessnewswire.com

Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended Decem

SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (th

accessnewswire.com

Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026

SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:RE

benzinga.com

12 Health Care Stocks Moving In Friday's After-Market Session

accessnewswire.com

Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds

SAN DIEGO, CA / ACCESS Newswire / January 23, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the

benzinga.com

12 Health Care Stocks Moving In Friday's Pre-Market Session

feeds.benzinga.com

Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours?

Revelation Biosciences shares jumped after the FDA agreed that a single Phase 2/3 study could suppor

benzinga.com

12 Health Care Stocks Moving In Thursday's Intraday Session

accessnewswire.com

Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI

- Single Phase 2/3 Adaptive Study Design - - Clinically Relevant, Objective Composite Endpoint - SAN

accessnewswire.com

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care

- Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study

accessnewswire.com

Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, CA / ACCESS Newswire / January 12, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the

accessnewswire.com

Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support La

SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the

defenseworld.net

Viking Therapeutics (NASDAQ:VKTX) and Revelation Biosciences (NASDAQ:REVB) Head to Head Contrast

Revelation Biosciences (NASDAQ: REVB - Get Free Report) and Viking Therapeutics (NASDAQ: VKTX - Get

accessnewswire.com

Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting

SAN DIEGO, CALIFORNIA / ACCESS Newswire / December 1, 2025 / Revelation Biosciences, Inc. (NASDAQ:RE

benzinga.com

US Stocks Likely To Open Higher: S&P 500 Sees 'Average Gain Of 6.1%' In 2nd Half, Expert Says

U.S. futures rose on Wednesday after a mixed close on Tuesday. Futures of major benchmark indices we

benzinga.com

Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

benzinga.com

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 838 companies hit new 52-week lows.

benzinga.com

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 340 stocks hit new 52-week lows.

benzinga.com

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's session saw 729 companies set new 52-week lows.

benzinga.com

Stocks That Hit 52-Week Highs On Tuesday

benzinga.com

Stocks That Hit 52-Week Highs On Tuesday